Enanta falls after co's RSV treatment fails main goal in mid-stage study

ReutersSep 29, 2025 11:09 AM

View all comments（0）



Shares of Enanta Pharmaceuticals ENTA.O fall 13.4% to $6.8 premarket

Co's experimental RSV treatment fails to meet the main goal of shortening the time taken to reduce the severity of some symptoms

However, the trial meets multiple secondary goals, including faster improvement on a patient‑reported severity measure and quicker time to when the virus was not detectable in the patient

As of last close, ENTA stock was up 37.3% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Samsung’s Largest Strike in History: Can SK Hynix and Micron Sit Back and Reap the Benefits?

TradingKey - On May 21, 61,000 union members at Samsung Electronics will launch an 18-day general strike, following a 93.1% approval vote. Government mediation between labor and management has collapsed.

Inflation 'High Fever' Fails to Stop Rally? BTC Temporarily Loses 80,000 Mark, But Arthur Hayes Sees Peak of $126,000

Higher-than-expected CPI data triggered a Bitcoin drop below $80,000, but the BitMEX co-founder remains staunchly bullish on BTC.

Copper Prices Near All-Time Highs. Citi: If Strait of Hormuz Is Unblocked, Price Will Rise to $15,000 by Year-End

TradingKey - Despite the ongoing US-Iran war and the continued closure of the Strait of Hormuz, copper prices maintain a solid floor. This Monday, LME (London Metal Exchange) three-month copper reached $13,637 per tonne at one point, marking its highest level since January 29. On the same day, LME three-month copper recorded a peak closing price of $13,952/tonne, with intraday prices briefly rising above $14,500/tonne.

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

SK Hynix Surges 15% to New High: HBM Shortage Until 2028, How Much Longer Can AI Memory King Rise?

TradingKey - During the Asian trading session on May 11, SK Hynix shares rose by more than 15% at one point, hitting an all-time intraday high of 1.949 million KRW, with its market capitalization surpassing $900 billion. The year-to-date cumulative gain is approximately 197.03%, with the share price nearly tripling.

Featured Tools